Subscribe To
ALLO / Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation
ALLO News
By Seeking Alpha
November 2, 2023
Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Christine Cassiano – Ch more_horizontal
By GlobeNewsWire
October 30, 2023
Allogene Therapeutics Announces Participation in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pion more_horizontal
By The Motley Fool
October 10, 2023
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate more_horizontal
By Seeking Alpha
August 2, 2023
Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief more_horizontal
By Zacks Investment Research
August 2, 2023
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares t more_horizontal
By Seeking Alpha
July 26, 2023
Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before
Allogene Therapeutics, Inc. is the leading developer of allogeneic CAR-T. There was a time when its logic appealed to me. Lately, however, I have incr more_horizontal
By GlobeNewsWire
July 26, 2023
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pion more_horizontal
By Zacks Investment Research
May 26, 2023
Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High?
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 210.2% upside in the stock. While this highly sought-after metric has more_horizontal